Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration
StockNews.AI · 8 hours
AI Summary
Invivyd today announced first participants dosed in LIBERTY, a Phase 3 trial comparing VYD2311, an mRNA COVID-19 vaccine, and their co-administration in healthy adults. Topline data are expected in Q3 2026, alongside results from DECLARATION. Positive tolerability signals could bolster the REVOLUTION program and support regulatory filings for VYD2311 if approved.
Sentiment Rationale
Phase 3 initiation with a near-term topline catalyst (Q3 2026) could improve sentiment and valuation if tolerability signals favor VYD2311; however, early-stage trial news generally leads to modest moves until data readouts.
Trading Thesis
Bullish: IVVD could trend higher ahead of LIBERTY topline data in 3Q2026 if tolerability signals favor the mAb.
Market-Moving
- LIBERTY topline data expected in Q3 2026; primary catalyst.
- Positive safety/tolerability signals vs mRNA vaccine could lift IVVD sentiment.
- DECLARATION read-across may influence regulatory timing and upside.
Key Facts
- LIBERTY Phase 3 dosed; topline data expected Q3 2026.
- Study compares VYD2311 vs mRNA vaccine safety/tolerability and co-administration effects.
- LIBERTY enrolls about 210 adults aged 18-49; triple-arm design.
- LIBERTY data to accompany anticipated regulatory filings for VYD2311.
- LIBERTY data to accompany DECLARATION pivotal results in 2026.
Companies Mentioned
- Invivyd (IVVD): Dosed first participants in LIBERTY Phase 3; data could influence REVOLUTION program and regulatory filings.
- Sanofi (SNY): COMPARE study cited; provides industry context on mAb-vs-vaccine tolerability.
Industry News
Invivyd's LIBERTY update is Industry News and Corporate Development aligned, signaling progress in the REVOLUTION program and potential pathway toward VYD2311's regulatory filings.